iShares Russell 2000 Growth Fund (NY:IWO)

360.84 +3.20 (+0.89%)

Official Closing Price Updated: 8:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about iShares Russell 2000 Growth Fund

< Previous 1 2 3 4 5 Next >

IWO vs. VOOG: How Small-Cap Diversification Compares to Large-Cap Growth ↗

March 26, 2026

Expense ratios, holdings breadth, and sector tilts set these two growth ETFs apart for investors.

Via The Motley Fool

Topics ETFs

IWO vs. VUG: One Offers Broad Growth Exposure While the Other Has Lower Fees ↗

March 26, 2026

Explore how portfolio composition and sector focus set these two growth ETFs apart for investors seeking different risk profiles.

Via The Motley Fool

Topics ETFs

IWO vs. MGK: Is Small-Cap Growth or Mega-Cap Tech the Better Choice for Investors? ↗

March 25, 2026

From sector focus to risk profiles, these two growth ETFs present sharply different paths for investors seeking portfolio diversification.

Via The Motley Fool

Topics ETFs

INMB Stock Rises Pre-Market – What Did The FDA Say About Its Alzheimer’s Trial? ↗

February 12, 2026

Via Stocktwits

Why Did Solaris Energy Stock Hit A 1-Year High Today? ↗

March 17, 2026

Barclays raised its price target on Solaris Energy to $74 from $63 and maintained an ‘Overweight’ rating on the shares, per TheFly.

Via Stocktwits

Topics Energy

Why Is GLSI Stock Rising Today? ↗

March 17, 2026

Greenwich LifeSciences said its Phase III breast cancer immunotherapy trial, involving 250 patients, showed a recurrence rate of under 1% per year.

Via Stocktwits

Topics Economy Government

Why Has TruBridge Delayed Its Planned Q4 Results? ↗

March 16, 2026

TruBridge said that it requires additional time for the completion of its year-end audit procedures.

Via Stocktwits

Topics Earnings

DigiMarc Stock Rallies After Hours On Q4 Revenue Beat ↗

March 11, 2026

DMRC’s total revenue for the fourth quarter of 2025 was $8.9 million compared to $8.7 million for the fourth quarter of 2024.

Via Stocktwits

Topics Intellectual Property

Why Is Micro-Cap Stock Blend Labs Surging After Hours? ↗

March 10, 2026

The company posted fourth quarter revenue of $32.4 million, an increase of 7% compared to the fourth quarter of 2024.

Via Stocktwits

Topics Artificial Intelligence

Why Did CDXS Stock Jump 7% Today? ↗

March 04, 2026

The company tied up with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA using a proprietary ECO Synthesis platform.

Via Stocktwits

Are Large-Cap or Small-Cap ETFs the Better Buy? Here's How SPY and IWO Stack Up on Risk and Returns ↗

March 02, 2026

Explore how sector focus and risk profiles set these two popular ETFs apart for investors weighing growth potential against stability.

Via The Motley Fool

Topics ETFs

Better ETF: iShares' Small-Cap IWO vs. Vanguard's Large-Cap VOO ↗

March 02, 2026

Cost, sector mix, and risk profiles set these ETFs apart. Explore how their differences may influence your approach to portfolio building.

Via The Motley Fool

Topics ETFs

BofA Survey: AI Bubble Just Became the Biggest Worry for Credit Investors ↗

March 02, 2026

The survey reveals 23% of institutional credit investors say an artificial intelligence (AI) bubble is their biggest worry.

Via The Motley Fool

Topics Artificial Intelligence Bonds Economy

AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial ↗

March 02, 2026

Aardvark Therapeutics shares saw brokerage downgrades after the company paused its Phase 3 trial to treat hyperphagia in patients with Prader-Willi syndrome.

Via Stocktwits

AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates ↗

February 26, 2026

Aurinia reported adjusted earnings per share of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.

Via Stocktwits

Why Did PVLA Stock Surge 45% In Pre-Market Today? ↗

February 24, 2026

The biotech company reported statistically significant Phase 3 data for QTORIN gel.

Via Stocktwits

Why Is IonQ Stock Surging After-Hours? ↗

February 23, 2026

IonQ is among more than 2,400 companies eligible to compete for future task orders issued under the SHIELD IDIQ contract framework.

Via Stocktwits

ATOM Stock Is Falling Pre-Market Today After Atomera Announces Stock Offering At A Deep Discount ↗

February 23, 2026

The company announced on Monday that it has entered into a definitive agreement to sell 5 million shares of its common stock at an offering price of $5 per share.

Via Stocktwits

ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? ↗

February 20, 2026

Analysts at H.C. Wainwright hiked their price target for Ardelyx shares to $18 from $10.

Via Stocktwits

Topics Earnings Intellectual Property

Invesco QQQ or iShares Russell 2000 Growth ETF: Which is the Better Buy? ↗

February 12, 2026

The Invesco QQQ is one of the most popular ETFs on the market. But is it the best growth-oriented ETF?

Via The Motley Fool

Topics ETFs

Why Did OUST Stock Catch Retail Attention In Pre-Market Today? ↗

February 09, 2026

The company announced that it completed the acquisition of AI vision specialist StereoLabs SAS earlier this month.

Via Stocktwits

Topics Artificial Intelligence

Small-Cap vs. Mega-Cap: Is IWO or MGK the Better Buy Right Now? ↗

February 08, 2026

Explore how sector mix and company size shape the risk and diversification profiles of these two popular growth ETFs.

Via The Motley Fool

Topics ETFs

Genius Sports’ Stock Is Down 26% Today – Why Is Retail Wary? ↗

February 05, 2026

Genius Sports said it is acquiring Legend in a transaction valued at up to $1.2 billion, including $900 million payable at closing and an earnout of up to $300 million.

Via Stocktwits

MDXG Stock Rises As MiMedx Enters Into Exclusive Distribution Agreement For Three Products ↗

February 04, 2026

According to the agreement, Summit Products Group will distribute Hydrelix, NovaForm, and G4Derm Plus, designed to complement MiMedx’s portfolio of leading surgical and wound products.

Via Stocktwits

Topics Artificial Intelligence

SOC Stock Declines 10% – What Are The Factors Driving The Selloff? ↗

February 03, 2026

The company disclosed that it has received subpoenas from the U.S. Attorney’s Office for the Southern District of New York and the SEC on reports of selective disclosure of material information to...

Via Stocktwits

Topics Government Law Enforcement Lawsuit

Why Did AQST Stock Jump 35% Today? ↗

February 02, 2026

The company received a Complete Response Letter from the U.S. Food and Drug Administration for its New Drug Application seeking approval of Anaphylm, a sublingual film to treat severe Type I allergic...

Via Stocktwits

Afraid of an AI Crash? These 3 Safer Plays Could Protect Your Portfolio. ↗

January 27, 2026

What if the AI bubble bursts in 2026? Here's how you can invest in a safer way in case AI stocks crash.

Via The Motley Fool

Topics Artificial Intelligence ETFs

IWO vs. VONG: How Does A Small Cap Growth Compare Against A Large Cap Growth Fund ↗

January 26, 2026

These two ETFs cover different Russell Growth Indexes, with different focuses. Here's what they can offer for someone's portfolio.

Via The Motley Fool

Topics ETFs

IWO vs. VUG: Comparing Growth ETFs With Different Focuses ↗

January 26, 2026

Explore how IWO’s small-cap diversity and sector mix set it apart from VUG’s concentrated large-cap approach.

Via The Motley Fool

Topics ETFs

IWO vs. MGK: How Small-Cap Diversification Compares to Mega-Cap Growth ↗

January 25, 2026

From sector tilts to portfolio concentration, key differences between these ETFs could shape your approach to growth investing.

Via The Motley Fool

Topics ETFs

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.